Valeria Estrada Navarro

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Breast Cancer Risk

Tyrosine Kinase

Top Venues

EMBO molecular medicine

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO molecular medicine 16 (8) (2024)
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO molecular medicine 16 (8) (2024)
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO molecular medicine (2024)
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. EMBO molecular medicine 16 (8) (2024)
Lauren Dong, Hyejin Choi, Sadna Budhu, Isabell Schulze, Svena Verma, Levi Mark Mangarin, Valeria Estrada Navarro, Nezar Mehanna, Jonathan F Khan, Divya Venkatesh, Daniel Thach, Neal X Rosen, Jedd D Wolchok, Taha Merghoub
Intermittent MEK inhibition with GITR co-stimulation rescues T-cell function for increased efficacy with CTLA-4 blockade in solid tumor models. Cancer immunology research (2024)